Australian company Imugene (ASX:IMU) has released new clinical data showing an 82 per cent overall response rate in its Phase 1b trial of azer-cel, the company’s allogeneic, off-the-shelf CD19 CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma. …
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech -
Pharmac scraps plan to remove low-ranked medicines from options for funding list
December 18, 2025 - - Latest News -
PBAC reflects on a year shaped by major reviews and rising workload
December 18, 2025 - - Latest News -
Priceline moves to stabilise banner group as pressures force administrators
December 17, 2025 - - Latest News -
Rare Cancers Australia gearing up for 2026 Kosi Challenge with Pharma Cup up for grabs again
December 17, 2025 - - Latest News